Clinical efficacy of direct DNA sequencing analysis on sputum specimens for early detection of drug-resistant Mycobacterium tuberculosis in a clinical setting

Chest

Volumn 137, Issue 2, 2010, Pages 393-400

  Choi, Jeong Hee ^a,b   Lee, Kyung Wha ^b   Kang, Hye Ryun ^a,b   Hwang, Yong Il ^a,b   Jang, Seunghun ^a,b   Kim, Dong Gyu ^a,b   Kim, Cheol Hong ^a,b   Hyun, In Gyu ^a,b   Shin, Tae Rim ^a,b   Park, Sang Myeon ^a,b   Lee, Myung Goo ^a,b   Lee, Chang Youl ^a,b   Park, Yong Bum ^a,b   Jung, Ki Suck ^a,b  

^a Hallym University   (South Korea)

^b Hallym University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; ETHAMBUTOL; ISONIAZID; KATG PROTEIN; PROTEIN EMBB; PROTEIN PNCA; PYRAZINAMIDE; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DNA SEQUENCE; DRUG EFFECT; DRUG TREATMENT FAILURE; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 76749084246     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-0150     Document Type: Article

References (24)

1. World Health Organization. WHO Report 2008. Global Tuberculosis Control: Surveillance, Planning, Financing. WHO/ HTM/TB/2008.393. Geneva, Switzerland; 2008.
2. World Health Organization. WHO Report 2008. Antituberculosis Drug Resistance in the World, Fourth Global Report: The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance 2002-2007. WHO/HTM/TB/2008.394. Geneva, Switzerland; 2008.
3. Bai GH, Park YK, Choi YW, et al. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis. 2007;11(5):571-576.
4. Statement of the American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med. 2000;161(4 Pt 1):1376-1395.
5. Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev. 1995;8(4): 496-514.
6. Telenti A, Imboden P, Marchesi F, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993;341(8846):647-650.
7. Haas WH, Schilke K, Brand J, et al. Molecular analysis of katG gene mutations in strains of Mycobacterium tuberculosis complex from Africa. Antimicrob Agents Chemother. 1997;41(7):1601-1603.
8. Telenti A, Philipp WJ, Sreevatsan S, et al. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat Med.1997;3(5):567-570.
9. Lee KW, Lee JM, Jung KS. Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea. J Korean Med Sci. 2001;16(5):537-543.
10. Escalante P, Ramaswamy S, Sanabria H, et al. Genotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from Peru. Tuber Lung Dis. 1998;79(2):111-118.
11. Van Rie A, Warren R, Mshanga I, et al. Analysis for a limited number of gene codons can predict drug resistance of Mycobacterium tuberculosis in a high-incidence community. J Clin Microbiol. 2001;39(2):636-641.
12. Yang Z, Durmaz R, Yang D, et al. Simultaneous detection of isoniazid, rifampin, and ethambutol resistance of Mycobacterium tuberculosis by a single multiplex allele-specific polymerase chain reaction (PCR) assay. Diagn Microbiol Infect Dis. 2005;53(3):201-208.
13. Miotto P, Piana F, Penati V, Canducci F, Migliori GB, Cirillo DM. Use of genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy. J Clin Microbiol. 2006;44(7):2485-2491.
14. Sekiguchi J, Miyoshi-Akiyama T, Augustynowicz-Kopeć E, et al. Detection of multidrug resistance in Mycobacterium tuberculosis. J Clin Microbiol. 2007;45(1):179-192.
15. Hillemann D, Rüsch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol. 2007;45(8):2635-2640.
16. Somoskovi A, Dormandy J, Mitsani D, Rivenburg J, Salfinger M. Use of smear-positive samples to assess the PCR-based genotype MTBDR assay for rapid, direct detection of the Mycobacterium tuberculosis complex as well as its resistance to isoniazid and rifampin. J Clin Microbiol. 2006;44(12):4459-4463.
17. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med. 2008;177(7):787-792.
18. World Health Organization. WHO Report 2003. Treatment of Tuberculosis. Guideline for National Programmes. WHO/ CDS/TB/2003.313. Geneva, Switzerland: World Health Organization; 2003.
19. Kim SJ, Bai GH, Hong YP. Drug-resistant tuberculosis in Korea, 1994. Int J Tuberc Lung Dis. 1997;1(4):302-308.
20. van Doorn HR, Kuijper EJ, van der Ende A, et al. The susceptibility of Mycobacterium tuberculosis to isoniazid and the Arg → Leu mutation at codon 463 of katG are not associated. J Clin Microbiol. 2001;39(4):1591-1594.
21. Rouse DA, Morris SL. Molecular mechanisms of isoniazid resistance in Mycobacterium tuberculosis and Mycobacterium bovis. Infect Immun. 1995;63(4):1427-1433.
22. Sreevatsan S, Stockbauer KE, Pan X, et al. Ethambutol resistance in Mycobacterium tuberculosis : critical role of embB mutations. Antimicrob Agents Chemother. 1997;41(8): 1677-1681.
23. Cheng SJ, Thibert L, Sanchez T, Heifets L, Zhang Y. pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. Antimicrob Agents Chemother. 2000;44(3): 528-532.
24. Kim DH, Kim HJ, Park SK, et al. Treatment outcomes and longterm survival in patients with extensively drug- resistant tuberculosis. Am J Respir Crit Care Med. 2008;178(10):1075-1082